Neuren Pharmaceuticals announced the appointment of Patrick Davies as non-executive Chair. The change follow Richard Treagus' decision to stand down after more than 7 years as Executive Chairman to enable him to focus on his other business interests. Jon has consistently played a key role alongside Richard in the business and has strong established relationships with business partners and investors. Together with the additional appointments made to strengthen the board two years ago, this means the Company is very well placed to make a smooth transition. Richard will be available to assist the board and management as the changes are implemented. Patrick joined the Neuren board as a non-executive director in July 2018 as part of changes to augment the skills and experience of the board for the next stage of development. His experience includes 10 years as CEO of EBOS Group (formerly Symbion) during which the enterprise value grew from $450 million to more than $3.1 billion. He provides strategic advice to a range of healthcare businesses and investors.